WHO Classification of tumors of the breast, 2012

Arkhiv Patologii

Volumn 75, Issue 2, 2013, Pages 53-63

  Frank, G A ^a,c   Danilova, N V ^a,c   Andreeva, Yu Yu ^c   Nefedova, N A ^b  

^a P A Herzen Research Oncological Institute   (Russian Federation)

^b MOSCOW STATE UNIVERSITY   (Russian Federation)

^c Russian Academy of Postgraduate Medical Training   (Russian Federation)

Author keywords

Breast cancer; Classification; Immunohistochemistry

Indexed keywords

BREAST TUMOR; CLASSIFICATION; FEMALE; HUMAN; PATHOLOGY; REVIEW; WORLD HEALTH ORGANIZATION;

BREAST NEOPLASMS; FEMALE; HUMANS; WORLD HEALTH ORGANIZATION;

EID: 84884758307     PISSN: 00041955     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Lakhani S.R., Ellis I.O., Schnht S.J., Tan P.H., vande Vijver M.J., eds. WHO classification of tumours of the breast. IARC/World health organization classification of tumours. Lyon, France: WHO Press; 2012.
2. Prasad M.L., Osborne M.P., Giri D.D., Hoda S.A. Microinvasive carcinoma (Tlmic) of the breast: clinicopathologic profile of 21 cases. Am. J. Surg. Pathol. 2000; 24 (3): 422-8.
3. Rakha E.A., El-Sayed M.E., Menon S., Green A.R., Lee A.H., Ellis 1.0. Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. Breast Cancer Res. Treat. 2008; 111(1): 121-7.
4. Consensus Conference on the classification of ductal carcinoma in situ. The Consensus Conference Committee. Cancer. 1997; 80 (9): 1798-802.
5. Abrial S.C., Penault-Llorca E, Delva R., Bougnoux P., Leduc B., Mouret-Reynier M.A. et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res. Treat. 2005; 94 (3): 255-63.
6. Fisher E.R., Wang J., Bryant J., Fisher B., Mamounas E., Wolmark N. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer. 2002; 95 (4): 681-95.
7. Chevallier B., Roche H., Olivier J.P., Chollet P., Hurteloup P. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am. J. Clin. Oncol. 1993; 16 (3): 223-8.
8. Symmans W.F., Peintinger E, Hatzis C, Rajan R., Kuerer H., Valero V. et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J. Clin. Oncol. 2007; 25 (28): 4414-22.
9. Carey LA., Metzger R., Dees E.C, Collichio E, Sartor C.I., Ollila D.W. et al. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J. Natl. Cancer Inst. 2005; 97 (15): 1137-42.
10. Greene EL., Page D.L., Fleming I.D., eds. AJCC cancer staging manual. Springer: New York; 2002.
11. Le Doussal V., Tubiana-Hulin M., Friedman S., Hacene K., Spyra-tos E, Brunei M. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer. 1989; 64 (9): 1914-21.
12. Pinder S.E., Provenzano E., Earl H., Ellis I.O. Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy. Histopathology. 2007; 50 (4): 409-17.